Propylactic Use of Entecavir for Biological Agents Associated Hepatitis B Virus Reactivation in Inflammatory Arthritis Patients: a Randomized Controlled Trial

Trial Profile

Propylactic Use of Entecavir for Biological Agents Associated Hepatitis B Virus Reactivation in Inflammatory Arthritis Patients: a Randomized Controlled Trial

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2016

At a glance

  • Drugs Entecavir (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Mar 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2018 as per ClinicalTrials.gov record.
    • 31 Mar 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2018 as per ClinicalTrials.gov record.
    • 31 Mar 2016 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top